A single injection of our Ebola vaccine provided 100% protection for mice exposed to Ebola virus. Marburg is an Ebola-like virus weaponized by hostile forces. Working directly with the United States Dept. of Defense, we are developing FlowVax Ebola & Marburg, a prophylactic nebulized biomedicine to protect at-risk military forces and civilians. By relying on T-cells rather than antibodies, FlowVax Ebola & Marburg provides long lasting protection through enhanced immune targeting and surveillance of the hidden Ebola and Marburg virus nucleocapsid proteins.

FlowVax Ebola & Marburg Vaccine Development is funded by the United States Department of Defense Chemical and Biological Defense Program.

Our vaccines create T-Cells that attack a specific segment of the “Nucleocapsid protein” (NP44-52) of Ebola, identified by the red arrow in the picture. By relying on T-cells rather than antibodies, FlowVax Ebola & Marburg provides long lasting protection through enhanced immune targeting and surveillance of the hidden Ebola and Marburg virus nucleocapsid proteins.